Press Releases
Momenta Discontinues Further Accrual of its Phase 2 Trial...
 The decision to discontinue enrollment into the study was based on the recommendation from the independent Data Safety Monitoring Board (DSMB) following a...
Press Releases
Novartis CDK4/6 inhibitor LEE011 receives FDA Breakthrough Therapy designation...
Novartis announced today that the US FDA has granted Breakthrough Therapy designation to LEE011 (ribociclib), in combination with letrozole, for the treatment of hormone receptor...
Press Releases
Amgen And Advaxis Enter Global Cancer Immunotherapies Collaboration
Amgen and Advaxis, Inc announced a global agreement for the development and commercialization of Advaxis' ADXS-NEO, a novel, preclinical investigational cancer immunotherapy treatment that is...
Press Releases
Pfizer and Western Oncolytics Announce Immuno-Oncology Research Collaboration to...
Companies plan to advance Western Oncolytics’ lead preclinical therapy into human testingPotential combination of WO-12 with Pfizer’s oncology pipeline could enhance therapeutic benefit in patients....
Press Releases
Economics Drives Thailand led Laboratory Market in ASEAN
Thailand, 2nd largest economy in South East Asia, promotes foreign investment with new S curve structure towards innovative, digital and research based economy, leading the...
Press Releases
Janssen Announces Clinical Collaboration with Bristol-Myers Squibb to Evaluate...
 Janssen Biotech, Inc.  announced it has entered into a clinical study collaboration agreement with Bristol-Myers Squibb Company to evaluate the combination of two immuno-oncology compounds...
Press Releases
FDA Approves First And Only Single Monthly Injection For...
Amgen announced that the U.S. FDA has approved the Repatha® (evolocumab) Pushtronex™ system (on-body infusor with prefilled cartridge), a new, monthly single-dose administration option.1 ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.